Sign In
Buy AZN
$183.02
+2.00 (+1.10%)
At Close: Jun 24, 2026
AstraZeneca places $85 million bet on autoimmune cell therapy with Quell deal
03:11am, Friday, 09'th Jun 2023
AstraZeneca PLC (LSE:AZN) is placing an $85 million bet on the autoimmune cell therapy sector with Quell Therapeutics - its latest licensing partner. As well as a promising single treatment 'cure
US FDA panel backs Sanofi-AstraZeneca's preventive RSV therapy
04:32pm, Thursday, 08'th Jun 2023
The U.S. Food and Drug Administration advisers on Thursday backed the use of Sanofi and partner AstraZeneca's experimental antibody to prevent respiratory syncytial virus (RSV) infections in infants.
FDA advisers vote in favor of AstraZeneca, Sanofi antibody for infant RSV protection
04:23pm, Thursday, 08'th Jun 2023
Advisers to the U.S. Food and Drug Administration voted unanimously Thursday to recommend a monoclonal antibody developed by Sanofi SNY, +1.30% and AstraZeneca AZN, +1.28% to protect infants from resp
FDA advisors recommend AstraZeneca antibody to protect babies from RSV
03:18pm, Thursday, 08'th Jun 2023
If the Food and Drug Administration approves nirsevimab, it will be the first medical intervention available in the U.S. that can protect infants from RSV.
GSK's RSV Vaccine Arexvy Gets EU Approval for Older Adults
02:34pm, Wednesday, 07'th Jun 2023
The approval of GSK's RSV vaccine for older adults is based on positive data from the pivotal AReSVi-006 phase III study.
AstraZeneca: Broker upbeat after American cancer conference data reveal
07:16am, Wednesday, 07'th Jun 2023
AstraZeneca PLC (LSE:AZN) presented significant new data at a recent global cancer conference, the American Society of Clinical Oncology (ASCO), that further underpins its investment case. That at lea
Options Traders Target Pharma Stock on FDA Buzz
03:06pm, Tuesday, 06'th Jun 2023
Options traders are blasting pharma stock AstraZeneca PLC (NASDAQ:AZN) today, after the U.S. Food and Drug Administration (FDA) failed to find any safety issues with the company's experimental respira
US FDA staff flag no new safety issues for Sanofi-AstraZeneca's preventive RSV therapy
10:29am, Tuesday, 06'th Jun 2023
The U.S. Food and Drug Administration's staff reviewers on Tuesday raised no new concerns on Sanofi and partner AstraZeneca's experimental therapy to prevent respiratory syncytial virus (RSV) infectio
AstraZeneca PLC (AZN) ASCO Investor Event
07:17am, Tuesday, 06'th Jun 2023
AstraZeneca PLC (NASDAQ:AZN ) ASCO Investor Event June 5, 2023 7:00 PM ET CorporateParticipants Andy Barnett - VP Global Head of IR Roy Herbst - Deputy Director, Yale Cancer Center Pascal Soriot - Chi
AstraZeneca (AZN) Anticoagulant Drug Study Meets Efficacy Goal
11:25am, Monday, 05'th Jun 2023
At the interim analysis, AstraZeneca's (AZN) drug Andexxa showed superior hemostatic efficacy or in other words improved control of bleeding with targeted anticoagulation reversal versus usual care.
Why Astrazeneca (AZN) is a Top Growth Stock for the Long-Term
10:55am, Monday, 05'th Jun 2023
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
AstraZeneca's Tagrisso slashes death risk in certain post-surgery lung cancer patients
08:04am, Sunday, 04'th Jun 2023
AstraZeneca's lung cancer therapy, Tagrisso, cut the risk of death by more than half in patients with a certain form of lung cancer who were diagnosed early enough to have their tumour surgically remo
FDA Expands AstraZeneca (AZN) Lynparza Label in Prostate Cancer
01:54pm, Friday, 02'nd Jun 2023
Following FDA's label-expansion approval, AstraZeneca's (AZN)/Merck's (MRK) Lynparza is the first PARP inhibitor approved in combination with a new hormonal agent in mCRPC.
Here's Why Astrazeneca (AZN) is a Strong Value Stock
10:53am, Friday, 02'nd Jun 2023
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
3 Nasdaq 100 Stocks That Are Surefire Buys in June
05:06am, Friday, 02'nd Jun 2023
The growth-focused Nasdaq 100 was hit hard in 2022 and lost a third of its value. Historically, double-digit percentage declines in the major stock indexes represent surefire buying opportunities.
